Ignite Creation Date:
2024-05-05 @ 11:31 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00062205
Status:
COMPLETED
Last Update Posted:
2010-02-09
First Post:
2003-06-05
Brief Title:
Imatinib Mesylate in Treating Patients With Recurrent Ewings Family of Tumors or Desmoplastic Small Round-Cell Tumor
Sponsor:
City of Hope Medical Center
Organization:
City of Hope Medical Center
Study Overview
Official Title:
Phase II Trial of Gleevec STI571 in Therapy of Ewings Family of Tumors and Desmoplastic Small Round Cell Tumors
Status:
COMPLETED
Status Verified Date:
2010-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth
PURPOSE This phase II trial is studying how well imatinib mesylate works in treating patients with recurrent Ewings family of tumors or desmoplastic small round-cell tumor
PURPOSE This phase II trial is studying how well imatinib mesylate works in treating patients with recurrent Ewings family of tumors or desmoplastic small round-cell tumor
Detailed Description:
OBJECTIVES
Determine the effectiveness of imatinib mesylate in patients with recurrent Ewings family of tumors or desmoplastic small round-cell tumor
Determine the toxic effects of this drug in these patients
Determine the duration of disease-free and overall survival of patients treated with this drug
OUTLINE This is an open-label study
Patients receive oral imatinib mesylate twice daily on days 1-28 Courses repeat every 28 days
PROJECTED ACCRUAL A total of 20-40 patients will be accrued for this study
Determine the effectiveness of imatinib mesylate in patients with recurrent Ewings family of tumors or desmoplastic small round-cell tumor
Determine the toxic effects of this drug in these patients
Determine the duration of disease-free and overall survival of patients treated with this drug
OUTLINE This is an open-label study
Patients receive oral imatinib mesylate twice daily on days 1-28 Courses repeat every 28 days
PROJECTED ACCRUAL A total of 20-40 patients will be accrued for this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CHNMC-IRB-02008 | US NIH GrantContract | None | httpsreporternihgovquickSearchP30CA033572 |
| P30CA033572 | NIH | None | None |